Practical use of a multicenter clinical research support system connected to electronic medical records

2021 ◽  
pp. 106362
Author(s):  
Shirou Manabe ◽  
Toshihiro Takeda ◽  
Atsushi Hattori ◽  
Masashi Yamamoto ◽  
Yoshie Shimai ◽  
...  
Keyword(s):  
Clinical Research ◽  
Electronic Medical Records ◽  
Support System ◽  
Medical Records ◽  
Research Support ◽  
Research Support System

scholarly journals Research Support System for Physics in Korea and Other Countries

2020 ◽  
Vol 29 (1/2) ◽  
pp. 7-13
Author(s):  
Yeonjin YI
Keyword(s):  
Support System ◽  
Research Support ◽  
Research Support System

scholarly journals PDB54 USE OF ELECTRONIC MEDICAL RECORDS FOR CLINICAL RESEARCH IN THE MANAGEMENT OF TYPE-2 DIABETES

2011 ◽  
Vol 14 (3) ◽  
pp. A101
Author(s):  
K.M. Kamal ◽  
L. Civitarese
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Research ◽  
Electronic Medical Records ◽  
Medical Records

A paper recommendation mechanism for the research support system Papits

2005 ◽  
Author(s):  
S. Watanabe ◽  
T. Ito ◽  
T. Ozono ◽  
T. Shintani
Keyword(s):  
Support System ◽  
Research Support ◽  
Research Support System

scholarly journals Methodological description of clinical research data collection through electronic medical records in a center participating in an international multicenter study

2019 ◽  
Vol 17 (4) ◽  
Author(s):  
Veronica Neves Fialho Queiroz ◽  
Andrea da Costa Moreira de Oliveira ◽  
Renato Carneiro de Freitas Chaves ◽  
Lucas Araújo de Borges Moura ◽  
Daniel Sousa César ◽  
...  
Keyword(s):  
Data Collection ◽  
Clinical Research ◽  
Electronic Medical Records ◽  
Multicenter Study ◽  
Medical Records ◽  
Research Data ◽  
International Multicenter Study ◽  
International Multicenter ◽  
Clinical Research Data

scholarly journals The Research Support System Administrated by STA.

1997 ◽  
Vol 45 (521) ◽  
pp. 348-351
Author(s):  
Yasutaka MORIGUCHI ◽  
Mitsuru OHNISHI
Keyword(s):  
Support System ◽  
Research Support ◽  
Research Support System

scholarly journals P280 Clinical burden of concomitant joint disease in psoriasis: a US-linked claims and electronic medical records database analysis

Rheumatology ◽  
2020 ◽  
Vol 59 (Supplement_2) ◽  
Author(s):  
William Tillett ◽  
Michelle Skornicki ◽  
Patricia Prince ◽  
Robert Suruki ◽  
Edward Lee ◽  
...  
Keyword(s):  
Metabolic Disease ◽  
Electronic Medical Records ◽  
Medical Records ◽  
Well Being ◽  
Skin Condition ◽  
Joint Disease ◽  
Research Support ◽  
Clinical Burden

Abstract Background Psoriasis (PSO) is an inflammatory skin condition, impacting physical and psychological well-being. PSO patients may develop psoriatic arthritis (PsA), a painful joint disease that further impacts quality of life. The objective was to examine rates of metabolic disease and depression in patients with PSO and PsA. Methods Claims data linked to electronic medical records were examined (Jan-2007-Mar-2018). Prevalent PSO patients were followed until end of data collection and categorized based on development of PsA (PSO+PsA cohort; defined by ICD9/10 codes in patients without PsA at baseline). Follow-up rates of comorbidities, including metabolic disease and depression, were compared for those with/without PsA, presented as cases per 1,000 patient-years (1000PY). Results Progression to PsA occurred in 2,311 (12%) patients. Follow-up rates of hyperlipidemia, hypertension, diabetes, and cardiovascular disease in the PSO+PsA cohort were 1.4-times (326 vs 234/1000PY), 1.6-times (357 vs 228/1000PY), 1.7-times (119 vs 72/1000PY), and 1.4-times (71 vs 50/1000PY) that observed in the PSO-only cohort, respectively. In patients without baseline metabolic disease, higher rates in PSO+PsA vs PSO-only remained (approximately 1.5-times and 1.3-times higher rates of hypertension and hyperlipidemia, respectively). The rate of depression was 140 vs 92/1000PY in the PSO+PsA vs PSO-only cohort; when examined in patients without baseline depression, rates were about half that observed in the overall population (72 vs 49/1000PY). Conclusion PSO+PsA patients had a substantial clinical burden, characterized by 40-70% higher rates of metabolic disease and depression than for patients who did not progress to PsA. Disclosures W. Tillett: Consultancies; AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB Pharma. Grants/research support; AbbVie, Celgene and Lilly. M. Skornicki: Other; Employee of Aetion. P. Prince: Other; Employee of Aetion. R. Suruki: Other; Employee of UCB Pharma. E. Lee: Other; Employee of UCB Pharma. A. Louder: Other; Employee of Aetion.

scholarly journals Rationale and protocol for the After Diabetes Diagnosis REsearch Support System (ADDRESS): an incident and high risk type 1 diabetes UK cohort study

BMJ Open ◽  
2017 ◽  
Vol 7 (7) ◽  
pp. e013956 ◽  
Author(s):  
Helen C Walkey ◽  
Akaal Kaur ◽  
Vassiliki Bravis ◽  
Ian F Godsland ◽  
Shivani Misra ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cohort Study ◽  
High Risk ◽  
Support System ◽  
Diabetes Diagnosis ◽  
Research Support ◽  
High Risk Type ◽  
Research Support System
Sign in / Sign up

Export Citation Format

Share Document